Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tremelimumab by AstraZeneca for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...
Tremelimumab by AstraZeneca for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...
Tremelimumab by AstraZeneca for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Tremelimumab by AstraZeneca for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According...
Tremelimumab by AstraZeneca for Laryngeal Cancer: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Tremelimumab by AstraZeneca for Gastric Cancer: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Tremelimumab by AstraZeneca for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase III for Kidney Cancer (Renal Cell Cancer). According to...
Tremelimumab by AstraZeneca for Ureter Cancer: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase III for Ureter Cancer. According to GlobalData, Phase III...
Tremelimumab by AstraZeneca for Urethral Cancer: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase III for Urethral Cancer. According to GlobalData, Phase III...
Tremelimumab by AstraZeneca for Bladder Cancer: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II...
Tremelimumab by AstraZeneca for Oropharyngeal Cancer: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
Tremelimumab by AstraZeneca for Soft Tissue Sarcoma: Likelihood of Approval
Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase...